United Therapeutics Corporation (UTHR) — Financial statements
Income statement, balance sheet, and cash flow for United Therapeutics Corporation — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 3,183↑10.6% | 2,877↑23.6% | 2,328↑20.2% | 1,936↑14.9% | 1,686 | |
| Cost of Revenue | 384↑24.1% | 310↑20.3% | 258↑75.5% | 147↑19.8% | 123 | |
| Gross Profit | 2,798↑9.0% | 2,568↑24.0% | 2,070↑15.7% | 1,790↑14.5% | 1,563 | |
| Operating Expenses | ||||||
| R&D Expenses | 550↑14.3% | 481↑17.9% | 408↑26.4% | 323↓40.2% | 540 | |
| General & Administrative Expenses | 613↑12.9% | 542↑37.2% | 395↓5.0% | 416↑3.4% | 403 | |
| Selling & Marketing Expenses | 119↑23.2% | 96↑17.7% | 82↑15.5% | 71↑9.9% | 64 | |
| SG&A Expenses | 731↑14.5% | 639↑33.9% | 477↓2.0% | 487↑4.3% | 467 | |
| Other Expenses | 0.00↓100.0% | 71 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 1,281↑7.6% | 1,191↑34.5% | 885↑9.3% | 810↓19.6% | 1,007 | |
| Total Costs & Expenses | 1,666↑11.0% | 1,500↑31.3% | 1,143↑19.4% | 957↓15.3% | 1,130 | |
| Operating Results | ||||||
| Operating Income | 1,517↑10.2% | 1,377↑16.2% | 1,185↑20.9% | 980↑76.2% | 556 | |
| Depreciation & Amortization | 86↑18.1% | 73↑36.3% | 53↑3.7% | 51↑2.8% | 50 | |
| EBITDA | 1,819↑9.9% | 1,654↑19.3% | 1,387↑33.3% | 1,040↑41.2% | 737 | |
| EBIT | 1,733↑9.6% | 1,582↑18.6% | 1,334↑34.8% | 989↑44.0% | 687 | |
| Interest & Other Income | ||||||
| Net Interest Income | 173↑10.4% | 156↑51.1% | 103↑707.8% | 13↑773.7% | -2 | |
| Interest Income | 192↓3.6% | 199↑22.4% | 163↑260.0% | 45↑170.7% | 17 | |
| Interest Expense | 20↓54.5% | 43↓27.7% | 59↑83.0% | 32↑74.2% | 19 | |
| Non-Operating Income | -216↓5.5% | -205↓37.8% | -149↓1498.9% | -9↑92.9% | -131 | |
| Other Income / Expenses | 197↑21.4% | 162↑81.2% | 89↑407.2% | -29↓176.6% | 38 | |
| Income Before Tax | 1,714↑11.4% | 1,539↑20.8% | 1,274↑34.1% | 951↑60.1% | 594 | |
| Income Tax Expense | 379↑10.3% | 344↑18.8% | 290↑29.6% | 223↑89.1% | 118 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | 1,335↑11.7% | 1,195↑21.4% | 985↑35.4% | 727↑52.9% | 476 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | 1,335↑11.7% | 1,195↑21.4% | 985↑35.4% | 727↑52.9% | 476 | |
| Bottom-Line Net Income | 1,335↑11.7% | 1,195↑21.4% | 985↑35.4% | 727↑52.9% | 476 | |
| EPS (Basic) | 30.13↑14.0% | 26.44↑25.7% | 21.04↑31.7% | 15.98↑50.8% | 10.60 | |
| EPS (Diluted) | 27.86↑13.1% | 24.64↑24.4% | 19.81↑32.1% | 15.00↑49.1% | 10.06 | |
| Weighted Average Shares | 44↓2.0% | 45↓3.4% | 47↑2.9% | 46↑1.3% | 45 | |
| Weighted Average Diluted Shares | 48↓1.2% | 49↓2.4% | 50↑2.5% | 49↑2.5% | 47 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.